William C Huang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/125000/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Partial Nephrectomy Versus Radical Nephrectomy in Patients With Small Renal Tumors—Is There a Difference in Mortality and Cardiovascular Outcomes?. Journal of Urology, 2009, 181, 55-62.	0.4	703
2	A Prospective, Blinded Comparison of Magnetic Resonance (MR) Imaging–Ultrasound Fusion and Visual Estimation in the Performance of MR-targeted Prostate Biopsy: The PROFUS Trial. European Urology, 2014, 66, 343-351.	1.9	344
3	Management of Small Renal Masses: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 2017, 35, 668-680.	1.6	262
4	Relationship Between Prebiopsy Multiparametric Magnetic Resonance Imaging (MRI), Biopsy Indication, and MRI-ultrasound Fusion–targeted Prostate Biopsy Outcomes. European Urology, 2016, 69, 512-517.	1.9	163
5	Patient-specific 3D printed and augmented reality kidney and prostate cancer models: impact on patient education. 3D Printing in Medicine, 2019, 5, 4.	3.1	121
6	Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine Plus Cisplatin in Patients With Muscle-Invasive Bladder Cancer. Journal of Clinical Oncology, 2018, 36, 1949-1956.	1.6	110
7	Predictive value of negative 3T multiparametric magnetic resonance imaging of the prostate on 12â€core biopsy results. BJU International, 2016, 118, 515-520.	2.5	109
8	Magnetic Resonance Imaging-Ultrasound Fusion Targeted Prostate Biopsy in a Consecutive Cohort of Men with No Previous Biopsy: Reduction of Over Detection through Improved Risk Stratification. Journal of Urology, 2015, 194, 1601-1606.	0.4	87
9	Management of Small Kidney Cancers in the New Millennium. JAMA Surgery, 2015, 150, 664.	4.3	75
10	Prebiopsy MRI and MRI-ultrasound Fusion–targeted Prostate Biopsy in Men With Previous Negative Biopsies: Impact on Repeat Biopsy Strategies. Urology, 2015, 86, 1192-1199.	1.0	71
11	The Institutional Learning Curve of Magnetic Resonance Imaging-Ultrasound Fusion Targeted Prostate Biopsy: Temporal Improvements in Cancer Detection in 4 Years. Journal of Urology, 2018, 200, 1022-1029.	0.4	64
12	Percutaneous Ablation Versus Partial and Radical Nephrectomy for T1a Renal Cancer. Annals of Internal Medicine, 2018, 169, 69.	3.9	64
13	Three-dimensional Printing and Augmented Reality: Enhanced Precision for Robotic Assisted Partial Nephrectomy. Urology, 2018, 116, 227-228.	1.0	61
14	The Role of Ipsilateral and Contralateral Transrectal Ultrasound-guided Systematic Prostate Biopsy in Men With Unilateral Magnetic Resonance Imaging Lesion Undergoing Magnetic Resonance Imaging-ultrasound Fusion-targeted Prostate Biopsy. Urology, 2017, 102, 178-182.	1.0	54
15	Discordance between Ureteroscopic Biopsy and Final Pathology for Upper Tract Urothelial Carcinoma. Journal of Urology, 2018, 199, 1440-1445.	0.4	53
16	Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial. Journal of Clinical Oncology, 2022, 40, 1312-1322.	1.6	42
17	Risk Stratification by Urinary Prostate Cancer Gene 3 Testing Before Magnetic Resonance Imaging-Ultrasound Fusion-targeted Prostate Biopsy Among Men With No History of Biopsy. Urology, 2017, 99, 174-179.	1.0	41
18	Use of MRI in Differentiation of Papillary Renal Cell Carcinoma Subtypes: Qualitative and Quantitative Analysis. American Journal of Roentgenology, 2016, 206, 566-572.	2.2	40

WILLIAM C HUANG

#	Article	IF	CITATIONS
19	"Pin the Tumor on the Kidney:―An Evaluation of How Surgeons Translate CT and MRI Data to 3D Models. Urology, 2019, 131, 255-261.	1.0	40
20	Prediction of Prostate Cancer Risk Among Men Undergoing Combined MRI-targeted and Systematic Biopsy Using Novel Pre-biopsy Nomograms That Incorporate MRI Findings. Urology, 2018, 112, 112-120.	1.0	36
21	Discriminative Ability of Commonly Used Indexes to Predict Adverse Outcomes After Radical Cystectomy: Comparison of Demographic Data, American Society of Anesthesiologists, Modified Charlson Comorbidity Index, and Modified Frailty Index. Clinical Genitourinary Cancer, 2018, 16, e843-e850.	1.9	31
22	High Response Rates to Neoadjuvant Chemotherapy in High-Grade Upper Tract Urothelial Carcinoma. Urology, 2019, 129, 146-152.	1.0	29
23	Update of the ICUD-SIU consultation on upper tract urothelial carcinoma 2016: treatment of localized high-risk disease. World Journal of Urology, 2017, 35, 327-335.	2.2	26
24	Pembrolizumab (pembro) in combination with gemcitabine (Gem) and concurrent hypofractionated radiation therapy (RT) as bladder sparing treatment for muscle-invasive urothelial cancer of the bladder (MIBC): A multicenter phase 2 trial Journal of Clinical Oncology, 2021, 39, 4504-4504.	1.6	26
25	Likert score 3 prostate lesions: Association between wholeâ€lesion ADC metrics and pathologic findings at MRI/ultrasound fusion targeted biopsy. Journal of Magnetic Resonance Imaging, 2016, 43, 325-332.	3.4	25
26	Chronic Kidney Disease and Kidney Cancer Surgery: New Perspectives. Journal of Urology, 2020, 203, 475-485.	0.4	25
27	Durable response to anti-PD-1 immunotherapy in epithelioid angiomyolipoma: a report on the successful treatment of a rare malignancy. , 2018, 6, 97.		19
28	Novel Use of Fluorescence Lymphangiography During Robotic Groin Dissection for Penile Cancer. Urology, 2017, 107, 267.	1.0	17
29	Current Trends in Renal Surgery and Observation for Small Renal Masses. Urologic Clinics of North America, 2017, 44, 169-178.	1.8	16
30	A workflow to generate patient-specific three-dimensional augmented reality models from medical imaging data and example applications in urologic oncology. 3D Printing in Medicine, 2021, 7, 34.	3.1	16
31	Impact of nephron sparing on kidney function and non-oncologic mortality. Urologic Oncology: Seminars and Original Investigations, 2010, 28, 568-574.	1.6	14
32	Pembrolizumab in the treatment of locally advanced or metastatic urothelial carcinoma: clinical trial evidence and experience. Therapeutic Advances in Urology, 2019, 11, 175628721983928.	2.0	13
33	Application of the PRECISION Trial Biopsy Strategy to a Contemporary Magnetic Resonance Imaging-Targeted Biopsy Cohort—How Many Clinically Significant Prostate Cancers are Missed?. Journal of Urology, 2021, 205, 740-747.	0.4	13
34	Surgery Insight: advances in techniques for open partial nephrectomy. Nature Reviews Urology, 2007, 4, 444-450.	1.4	12
35	Patterns of surveillance imaging after nephrectomy in the <scp>M</scp> edicare population. BJU International, 2016, 117, 280-286.	2.5	12
36	Personalized Treatment for Small Renal Tumors: Decision Analysis of Competing Causes of Mortality. Radiology, 2019, 290, 732-743.	7.3	12

3

WILLIAM C HUANG

#	Article	IF	CITATIONS
37	Correlation of DNA damage response (DDR) gene alterations with response to neoadjuvant (neo) dose-dense gemcitabine and cisplatin (ddGC) in urothelial carcinoma (UC) Journal of Clinical Oncology, 2016, 34, 5011-5011.	1.6	12
38	Different models for prediction of radical cystectomy postoperative complications and care pathways. Therapeutic Advances in Urology, 2019, 11, 175628721987558.	2.0	11
39	Impact of type of minimally invasive approach on open conversions across ten common procedures in different specialties. Surgical Endoscopy and Other Interventional Techniques, 2022, 36, 6067-6075.	2.4	11
40	Management of Small Kidney Tumors in 2019. JAMA - Journal of the American Medical Association, 2019, 321, 1622.	7.4	9
41	Minimally Invasive Surgery for Patients with Locally Advanced and/or Metastatic Renal Cell Carcinoma. Urologic Clinics of North America, 2020, 47, 389-397.	1.8	9
42	Neoadjuvant atezolizumab (A) with gemcitabine and cisplatin (GC) in patients (pts) with muscle-invasive bladder cancer (MIBC): A multicenter, single-arm, phase 2 trial Journal of Clinical Oncology, 2021, 39, 4517-4517.	1.6	9
43	Primary Chemoablation of Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer Using UGN-102, a Mitomycin-Containing Reverse Thermal Gel (Optima II): A Phase 2b, Open-Label, Single-Arm Trial. Journal of Urology, 2022, 207, 61-69.	0.4	9
44	A prospective comparative analysis of the accuracy of HistoScanning and multiparametric magnetic resonance imaging in the localization of prostate cancer among men undergoing radical prostatectomy. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 3.e1-3.e8.	1.6	8
45	Influence of renal biopsy results on the management of small kidney cancers in older patients: Results from a population-based cohort. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 604.e1-604.e9.	1.6	8
46	Effect of Malnutrition on Radical Nephroureterectomy Morbidity and Mortality: Opportunity for Preoperative Optimization. Clinical Genitourinary Cancer, 2018, 16, e807-e815.	1.9	7
47	Development of a Novel Prognostic Risk Score for Predicting Complications of Penectomy in the Surgical Management of Penile Cancer. Clinical Genitourinary Cancer, 2019, 17, e123-e129.	1.9	7
48	Multicenter prospective phase II trial of neoadjuvant (neo) dose dense gemcitabine and cisplatin (DD-GC) in patients (pts) with muscle-invasive bladder cancer (MIBC) Journal of Clinical Oncology, 2016, 34, 436-436.	1.6	6
49	Rational approach to the treatment of a patient with a small renal cortical tumor. Nature Reviews Urology, 2007, 4, 688-691.	1.4	4
50	Small Kidney Tumors. JAMA - Journal of the American Medical Association, 2019, 322, 588.	7.4	3
51	Safety of repeat blue light cystoscopy with hexaminolevulinate (HAL) in the management of bladder cancer: Results from a phase III, comparative, multi-center study. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 382.e1-382.e6.	1.6	3
52	Evolving Treatment Paradigms for Renal Cancer. Urologic Clinics of North America, 2012, 39, xiii-xiv.	1.8	2
53	Impact of immunonutrition on radical cystectomy immunoresponse and outcomes; opportunity for peri-operative optimization. Translational Andrology and Urology, 2018, 7, S760-S762.	1.4	2
54	Current Landscape of Advanced and Metastatic Renal Cell Carcinoma Management. Urologic Clinics of North America, 2020, 47, xiii-xiv.	1.8	2

WILLIAM C HUANG

#	Article	IF	CITATIONS
55	Prognostic Value of Histologic Subtype and Treatment Modality for T1a Kidney Cancers1. Kidney Cancers Cancer, 2020, 4, 49-58.	0.4	2
56	Machine learning decision support model for radical cystectomy discharge planning. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 453.e9-453.e18.	1.6	2
57	Novel role of X-linked inhibitor of apoptosis protein (XIAP) in bladder cancer cell invasion and prediction of disease progression Journal of Clinical Oncology, 2014, 32, e15504-e15504.	1.6	1
58	Does histologic subtype impact overall survival in observed T1a kidney cancers compared with competing risks? Implications for biopsy as a risk stratification tool. International Journal of Urology, 2022, , .	1.0	1
59	Editorial Comment. Urology, 2013, 81, 579-580.	1.0	Ο
60	Editorial Comment. Urology, 2013, 81, 345-346.	1.0	0
61	Editorial Comment. Journal of Urology, 2014, 192, 1062-1063.	0.4	0
62	Re: Maxine Sun, Andreas Becker, Zhe Tian, et al. Management of Localized Kidney Cancer: Calculating Cancer-specific Mortality and Competing Risks of Death for Surgery and Nonsurgical Management. Eur Urol 2014;65:235–41. European Urology, 2015, 67, e71.	1.9	0
63	Re: Pak et al.: Utilization Trends and Short-term Outcomes of Robotic Versus Open Radical Cystectomy for Bladder Cancer (Urology 2017;103:117-123) and Borza et al.: No Differences in Population-based Readmissions After Open and Robotic-assisted Cystectomy: Implications for Post-discharge Care (Urology 2017:104:77-83), Urology, 2017, 105, 211.	1.0	0
64	AUTHOR REPLY. Urology, 2019, 129, 151-152.	1.0	0
65	Overall Survival of Biopsy-confirmed T1B and T2A Kidney Cancers Managed With Observation: Prognostic Value of Tumor Histology. Clinical Genitourinary Cancer, 2021, 19, 280-287.	1.9	Ο
66	Robotic Pelvic Exenteration (Cystoprostatectomy and Combined Abdominoperineal Resection) with Double-Barreled Wet Colostomy. Journal of Laparoendoscopic & Advanced Surgical Techniques Part B, Videoscopy, 2017, 27, .	0.2	0
67	Immunosuppressive milieu of high-risk localized prostate cancer Journal of Clinical Oncology, 2020, 38, 344-344.	1.6	0
68	Use of 3D Printed Models for Complex Renal Surgery: Two Case Presentations: NYU Case of the Month, May 2019. Reviews in Urology, 2019, 21, 118-122.	0.9	0
69	Diagnostic role of urine cytology and ureteroscopic biopsies in detection of high grade upper tract urothelial carcinoma. American Journal of Clinical and Experimental Urology, 2021, 9, 221-228.	0.4	0